GSA Capital Partners’s iShares US Pharmaceuticals ETF IHE Stock Holding History

GSA Capital Partners’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,547	Closed	-$216K	–	1928
2025 Q4	$216K	Sell	2,547 -1,593	-38%	-$127K	0.02%	1363
2025 Q3	$300K	Buy	+4,140	New	+$286K	0.03%	1197
2025 Q2	–	Sell	-3,101	Closed	-$219K	–	1929
2025 Q1	$219K	Sell	3,101 -1,460	-32%	-$101K	0.02%	1354
2024 Q4	$300K	Buy	4,561 +1,515	+50%	+$104K	0.02%	1203
2024 Q3	$215K	Sell	3,046 -1,225	-29%	-$85.4K	0.02%	1394
2024 Q2	$283K	Sell	4,271 -7,425	-63%	-$487K	0.02%	1303
2024 Q1	$794K	Buy	11,696 +4,649	+66%	+$307K	0.06%	602
2023 Q4	$436K	Buy	7,047 +2,490	+55%	+$146K	0.04%	886
2023 Q3	$269K	Buy	4,557 +435	+11%	+$26.7K	0.02%	1140
2023 Q2	$246K	Buy	+4,122	New	+$245K	0.02%	1158
2022 Q1	–	Sell	-3,552	Closed	-$236K	–	1590
2021 Q4	$236K	Buy	3,552 +186	+6%	+$11.8K	0.03%	1108
2021 Q3	$205K	Buy	+3,366	New	+$214K	0.02%	1225

Other funds holding IHE

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

FIA

Foundations Investment Advisors Phoenix, Arizona $9.72B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ACA

Aptus Capital Advisors Fairhope, Alabama $14.6B AUM 22.78% 1-Year Est. Return

MSCM

McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

ACM

Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

IWS

Insight Wealth Strategies San Ramon, California $1.01B AUM 28.81% 1-Year Est. Return

GSA Capital Partners's IHE Position: Q1 2026 in Review

GSA Capital Partners sold out of iShares US Pharmaceuticals ETF (IHE) in Q1 2026, closing a stake of 2,547 shares — an estimated $216K sold.

GSA Capital Partners first reported a position in IHE in Q3 2021 and held it in 12 quarters. The position peaked at $794K in Q1 2024. 194 funds tracked by Wall St. Rank hold IHE as of Q1 2026.

GSA Capital Partners reported no remaining iShares US Pharmaceuticals ETF position as of Q1 2026 after selling out during the quarter.
GSA Capital Partners sold 2,547 iShares US Pharmaceuticals ETF shares in Q1 2026, an estimated $216K.
GSA Capital Partners first reported a position in iShares US Pharmaceuticals ETF in Q3 2021 and held it in 12 quarters.
GSA Capital Partners's iShares US Pharmaceuticals ETF position peaked at $794K in Q1 2024.
194 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.